<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite major improvements on the knowledge and clinical management, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is still a deadly disease </plain></SENT>
<SENT sid="1" pm="."><plain>Novel biomarkers for better <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> detection, diagnosis and treatment prediction are urgently needed </plain></SENT>
<SENT sid="2" pm="."><plain>Proteins secreted, shed or leaking from the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell, collectively termed the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> secretome, are promising biomarkers since they might be detectable in blood or other biofluids </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> secretome in part represents the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment that plays a key role in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> promoting processes such as <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and invasion </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> secretome, sampled as conditioned medium from cell lines, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>/tissue interstitial fluid or <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> proximal body fluids, can be studied comprehensively by nanoLC-MS/MS-based approaches </plain></SENT>
<SENT sid="5" pm="."><plain>Here, we outline the importance of current <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> secretome research and describe the mass spectrometry-based analysis of the secretome </plain></SENT>
<SENT sid="6" pm="."><plain>Further, we provide an overview of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> secretome research with a focus on the three most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types: lung, breast and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> secretome research field is a young, but rapidly evolving research field </plain></SENT>
<SENT sid="8" pm="."><plain>Up to now, the focus has mainly been on the discovery of novel promising secreted <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> biomarker proteins </plain></SENT>
<SENT sid="9" pm="."><plain>An interesting finding that merits attention is that in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> unconventional secretion, e.g. via vesicles, seems increased </plain></SENT>
<SENT sid="10" pm="."><plain>Refinement of current approaches and methods and progress in clinical validation of the current findings are vital in order to move towards applications in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> management </plain></SENT>
<SENT sid="11" pm="."><plain>This article is part of a Special Issue entitled: An updated secretome </plain></SENT>
</text></document>